AH
Assort HealthAssort Health builds AI voice agents that automate patient access workflows for healthcare organizations, including scheduling, intake, referrals, and insurance verification.
2 Pulse stories
AT
Attovia TherapeuticsAttovia Therapeutics is a clinical-stage biotech developing ATTOBODY-based biotherapeutics for immune-mediated diseases that went public on Nasdaq in August 2026 in an upsized IPO raising ~$332M gross.
8 Pulse stories
Total Raised
$222M
~$588M ($256M private + $332M IPO gross incl. greenshoe, Aug 2026)
Assort HealthAttovia Therapeutics
Last Valuation
$1.2B
$767M at IPO pricing; ~$904M market cap at Nasdaq open (Aug 5, 2026)
Assort HealthAttovia Therapeutics
Biotech
Sector
Biotech
2023
Founded
2023
San Francisco, California
HQ
San Carlos, CA
Private
Status
Public (ATTO)
Assort Health investors
Menlo VenturesLightspeed Venture PartnersFelicisFirst Round CapitalChemistryLiquid 2 VenturesQuiet CapitalA* Capital
Attovia Therapeutics investors
venBio PartnersGoldman Sachs AlternativesFrazier Life SciencesDeep Track CapitalIllumina VenturesSanofi VenturesEcoR1 Capital
Data from Value Add Pulse coverage and company research — see the full threads for Assort Health and Attovia Therapeutics.